Continued from page 1

Paul Ceglia’s lead attorney, Dean Boland, said Monday that the addition of lawyers from the New York firm Milberg LLP and elsewhere is an indication of the case’s strength.

Mr. Ceglia is suing Facebook and founder Mark Zuckerberg in federal court in Buffalo. Mr. Ceglia says a contract he signed with the then-freshman at Harvard University in 2003 entitles him to half of the multibillion-dollar social networking site.

Lawyers for the Menlo Park, Calif.-based company say the contract is doctored and had nothing to do with Facebook. A Facebook spokesman declined to comment Monday.

The social networking site has 845 million users and recorded $3.7 billion in revenue last year.


Merck: FDA won’t OK combo cholesterol drug

WHITEHOUSE STATION — Federal regulators have decided not to approve a new combination cholesterol drug made by Merck & Co., at least for now.

The drug-maker says the Food and Drug Administration informed the company it will need more data before it can approve the medicine.

The Merck experimental drug combines the company’s cholesterol drug Zetia with a generic version of rival Pfizer Inc.’s Lipitor, which had been the top-selling drug of all time.

Merck says company officials will talk with the FDA to determine the next steps for trying to win approval. Merck says some new data expected later this year may address the FDA’s concerns.

From wire dispatches and staff reports